Highest-materiality recent filing
Cullinan reports initial Phase 1 data for CLN-978: B cell depletion and early efficacy in RA/SLE
As of Jan 14, 2026 cutoff, 14 patients dosed (5 RA, 9 SLE) across cohorts 1-3.
Net loss of $49.7M for Q1 2026 vs $48.5M in Q1 2025; R&D expense $42.1M, G&A $11.6M.
Cullinan reports $439M cash, $219.9M net loss; CLN-978 data and zipalertinib NDA on track
Cash and investments of $439.0M as of Dec 31, 2025; runway into 2029.
Cullinan Therapeutics reports 31% CR/CRh rate at 12 µg/kg for CLN-049 in R/R AML Phase 1
At 12 µg/kg (n=16), CR/CRh rate 31% (5/16) and CRc rate 31% (5/16); at ≥6 µg/kg (n=32), CR/CRh 25% and CRc 28%.
Cullinan Therapeutics terminates exclusive MIT license for CLN-617; program abandoned
Terminates Exclusive Patent License Agreement with MIT for CLN-617, effective Feb 18, 2026.
Cullinan Q3 net loss $50.6M; focuses on T cell engagers; cash runway into 2029
Net loss $50.6M vs $40.6M YoY; R&D expense $42.0M, G&A $13.6M.
Cullinan reports Phase 1 CLN-049 data: 31% CRc at 12 μg/kg in r/r AML
Anti-leukemic activity at doses ≥6 μg/kg: CRc 30%, ORR 57% (n=23); at 12 μg/kg CRc 31%, ORR 69% (n=13).
Cullinan Q2 net loss $70.1M, cash $510.9M; appoints new directors; CLN-978 enrolling
Q2 2025 net loss $70.1M vs $42.0M; R&D expenses $61.0M vs $36.3M; cash and investments $510.9M providing runway into 2028.
Upfront license fee of $20 million; Genrix eligible for up to $292M in development/regulatory milestones and up to $400M in sales-based milestones.
Cullinan Q1 net loss $48.5M; CLN-978 gains EMA approval for RA, expands into Sjögren's
Net loss of $48.5M in Q1 2025 vs $37.1M in Q1 2024; R&D expenses rose to $41.5M.
Cullinan Therapeutics reports Q4/FY 2024 results; zipalertinib pivotal study met endpoint
Cash and investments of $606.9M at Dec 31, 2024; runway extended into 2028.
REZILIENT1 trial met primary endpoint of overall response rate in NSCLC with EGFR exon 20 insertion mutations after prior therapy.
Cullinan Therapeutics Q3 net loss $40.6M; cash $639M; CLN-978 IND cleared for SLE Phase 1
Net loss $40.6M ($0.69/sh) vs $39.2M ($0.91/sh) in Q3 2023; cash $639M provides runway to 2028.
Cullinan Therapeutics receives FDA IND clearance for CLN-978 in moderate-to-severe SLE
FDA cleared IND for CLN-978, a CD19 T cell engager, in systemic lupus erythematosus.
Cullinan Q2 net loss $42M; cash $664.9M; advancing CLN-978 IND in SLE for Q3 2024
Net loss $42.0M vs $32.2M Q2 2023; R&D $36.3M, G&A $13.8M; cash runway into 2028.
Cullinan reports Phase 2b zipalertinib data: 39% ORR in post-amivantamab NSCLC patients
ORR of 39% (confirmed) and DCR of 94% in 18 evaluable patients; median DOR and PFS not yet reached.
Cullinan announces CLN-619+Keytruda shows PRs in EGFR/ALK NSCLC; monotherapy CR in parotid
Combination with pembrolizumab: 3 confirmed PRs in NSCLC (EGFR/ALK) and gastric patients typically CPI-unresponsive.
Cash, cash equivalents, investments $434.8M as of March 31, 2024; plus $280M April private placement extends cash runway into 2028.
Cullinan Therapeutics hires Mary Kay Fenton as CFO; $495k salary, 200k-share option grant
Mary Kay Fenton appointed CFO effective April 29, 2024; previously CFO of Talaris Therapeutics.
Cullinan raises $280M, pivots to autoimmune with promising CLN-978 data; cash runway into 2028
$280M private placement at $19/share; pre-funded warrants $18.999; extends cash runway into 2028.
Cullinan Oncology reports Q4 2023 net loss of $25.6M; CFO Trigilio to depart Mar 29
Net loss for FY 2023 was $155.1M vs income of $109.2M in 2022; Q4 loss $25.6M.
the Board of Directors (the “Board”) of the Company appointed David Meek as a Class I director, effective May 15, 2024.
Thomas Ebeling notified the Board of his intention to serve out his current term and resign as a director effective as of June 26, 2024.
On April 29, 2024, Cullinan Therapeutics, Inc. (the “Company”) announced the hiring and appointment of Mary Kay Fenton as the Company’s Chief Financial Officer, effective immediately.
Max materiality 0.85 · Median 0.70 · Most common event earnings